^
    Back
    Association details:
    Biomarker:KIF5B-RET fusion
    Cancer:Lung Adenocarcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Sci Rep
    Title:

    Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene

    Published date:
    06/25/2020
    Excerpt:
    A 43-year-old female patient with metastatic lung adenocarcinoma, who harbored KIF5B-RET fusion and had highly positive PD-L1 staining, received nivolumab as second-line treatment. A partial response was achieved and remained for more than five months.
    DOI:
    10.1038/s41598-020-66883-0